Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world
暂无分享,去创建一个
Kazuhisa Takahashi | S. Togo | Motoyasu Kato | S. Sasaki | Y. Arai | H. Motomura | I. Sumiyoshi | Y. Ochi | J. Watanabe | H. Ihara | K. Kadoya | Takuto Sueyasu | S. Soma | T. Akimoto | W. Mori | E. Hayakawa | Haruki Hirakawa | Kazuaki Hoshi | Makiko Kohmaru | Naho Sakamoto Matsubara | Shun Nakazawa | Jia Hou
[1] F. Martinez,et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2022, American journal of respiratory and critical care medicine.
[2] P. Brillet,et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2021, The Lancet. Respiratory medicine.
[3] Jonathan H. Chung,et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline , 2020, American journal of respiratory and critical care medicine.
[4] M. Ando,et al. Acute exacerbations of fibrotic interstitial lung diseases , 2020, Respirology.
[5] Y. Hara,et al. Diffuse alveolar hemorrhage complicating acute exacerbation of IPF , 2020, Respiratory medicine case reports.
[6] T. Johkoh,et al. Thrombomodulin alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Randomized, Double-blind, Placebo-controlled Trial. , 2020, American journal of respiratory and critical care medicine.
[7] S. Walsh,et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. , 2019, The New England journal of medicine.
[8] Shinichi Sasaki,et al. Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis , 2019, Scientific Reports.
[9] D. Hashimoto,et al. Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score‐matched analysis , 2019, Respirology.
[10] G. Raghu,et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.
[11] A. Gemma,et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. , 2019, The Lancet. Oncology.
[12] T. Kishaba. Evaluation and management of Idiopathic Pulmonary Fibrosis. , 2019, Respiratory investigation.
[13] F. Sakamaki,et al. Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases , 2019, Respiratory medicine case reports.
[14] J. Huggins,et al. Acute exacerbations of progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.
[15] Takeshi Johkoh,et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.
[16] A. Gemma,et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. , 2018, Respiratory investigation.
[17] P. Pelosi,et al. Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome? , 2018, Critical Care.
[18] Y. Sugiyama,et al. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials , 2017, Respirology.
[19] H. Collard,et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis , 2017, European Respiratory Journal.
[20] H. Tomioka,et al. Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis , 2017, Respirology case reports.
[21] D. Lynch,et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. , 2016, American journal of respiratory and critical care medicine.
[22] Y. Nishioka,et al. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis , 2015, Core evidence.
[23] Shandra L. Protzko,et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. , 2015, American journal of respiratory and critical care medicine.
[24] M. Bando,et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. , 2014, American journal of respiratory and critical care medicine.
[25] N. Katakami,et al. The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease , 2014, Cancer Chemotherapy and Pharmacology.
[26] M. Nakazato,et al. Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis , 2014, Respiratory Research.
[27] T. Choueiri,et al. The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients , 2012, Current Oncology Reports.
[28] R. Kaiser,et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] R. Kaiser,et al. Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors , 2010, Molecular Cancer Therapeutics.
[30] T. Kozuka,et al. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.
[31] W. Sommergruber,et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.
[32] D. McDonald,et al. Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.
[33] Zhen-hua Li. [The treatment of idiopathic pulmonary fibrosis]. , 2007, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.
[34] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[35] A. Millar,et al. Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm? , 2006, Thorax.
[36] S. Kudoh,et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2005, American journal of respiratory and critical care medicine.
[37] P. Schwartzberg,et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. , 1999, Molecular cell.
[38] Y. Kawabata,et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. , 1993, Chest.
[39] O. Dogar. in with a randomised, double-blind, placebo-controlled phase 3 trial , 2021 .
[40] Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.
[41] M. L. R. D. Christenson,et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management , 2012 .